1. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818.

2. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.

3. Mancia G, Fagard R, Narkiewicz K i wsp. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34(28): 2159-2219.

4. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2014. Stanowisko Polskiego Towarzystwa Diabetologicznego. Diabetologia Kliniczna 2014; 3(supl. A): A1- A71.

5. Barylski M, Banach M, Filipiak KJ. Budowa chemiczna i właściwości farmakologiczne statyn. W: Aktualny stan wiedzy na temat statyn – wydanie II zmienione i uzupełnione, pod red. Macieja Banacha, Krzysztofa J. Filipiaka i Grzegorza Opolskiego. Termedia Wydawnictwa Medyczne, Poznań 2013, s. 31-46.

6. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol 2005; 19: 117-125.

7. Chruściel P, Serwa-Stępień E, Banach M, Barylski M. Właściwości poszczególnych preparatów statyn. W: Aktualny stan wiedzy na temat statyn - wydanie II zmienione i uzupełnione, pod red. Macieja Banacha, Krzysztofa J. Filipiaka i Grzegorza Opolskiego. Termedia Wydawnictwa Medyczne, Poznań 2013, s. 81-154.

8. Graham DI, Staffa IA, Shatin D i wsp. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004; 292: 2585-2590.

9. Tomlinson SS, Mangione KK. Potential adverse effects of statins on muscle. Phys Ther 2005; 85: 459-465.

10. Vasudevan AR, Hamirani YS, Jones PH. Safety of statins: effects on muscle and the liver. Cleve Clin J Med 2005; 72: 990-1001.

11. Jones PH, Davidson MH, Stein EA i wsp.; STELLAR Study Group. Comparison of the efficacy and safety o rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003; 92: 152-160.

12. Barylski M. Atorwastatyna i rosuwastatyna w chorobach układu sercowo-naczyniowego - dlaczego, kiedy i u kogo je stosować? Geriatria 2012; 6: 166-182.

13. Wożakowska-Kapłon B, Barylski M, Salwa P i wsp. Zalecenia postępowania w dyslipidemii – propozycje algorytmu dla lekarzy rodzinnych. Forum Med Rodz 2012; 6: 261-282.

14. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Metaanalysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010; 105: 69-76.

15. Kendrach MG, Kelly-Freeman M. Approximate equivalent rosuvastatin doses for temporary statin interchange programs. Ann Pharmacother 2004; 38(7-8): 1286-1292.

16. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010; 376(9753): 1658-1669.

17. LaRosa JC, Grundy SM, Waters DD i wsp.;, for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronarydisease. N Eng J Med 2005; 352: 1425-1435.

18. Atorvastatin versus Revascularisation Treatment Investigators (AVERT): Aggressive lipid lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70-84.

19. Koren MJ, Hunninghake DB; ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 2004; 44: 1772-1779.

20. Olsson AG, Schwartz GG, Szarek M i wsp. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short term prognosis after acute coronarysyndrome: results from the MIRACL trial. Eur Heart J 2005; 26: 890-896.

21. Ray KK, Cannon CP, McCabe CH i wsp. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46: 1405-1410.

22. Colhoun HM, Betteridge DJ, Durrington PN i wsp. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.

23. Sever PS, Dahlof B, Poulter NR i wsp. Prevention of coronary and stroke events withatorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.

24. Amarenco P, Bogousslavsky J, Callahan A 3rd i wsp.; for the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-559.

25. Nissen SE, Nicholls SJ, Sipahi I i wsp. Effect of very highintensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556-1565.

26. Nicholls SJ, Ballantyne CM, Barter PJ i wsp. Effect of the intensive statin regiments on progression of coronary disease. N Engl J Med 2011; 365: 2078-2087.

27. Ridker PM, Danielson E, Fonseca FA i wsp. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359: 2195-2207.

28. Crestor prescribing information in the United States. http:// www1.astrazeneca-us.com/pi/crestor.pdf (5 May 2010).

29. Crestor prescribing information in the UK. http://www.medicines. org.uk/EMC/medicine/11976/SPC/Crestor+5mg% 2c+10mg%2c+20mg+and+40mg+film-coated+tablets/ (24 May 2010).

30. Wożakowska-Kapłon B, Filipiak KJ, Mamcarz A i wsp. Aktualne problemy terapii dyslipidemii w Polsce – II Deklaracja Sopocka. Stanowisko grupy ekspertów wsparte przez Sekcję F farmakoterapii Sercowo-Naczyniowej Polskiego Towarzystwa Kardiologicznego. Kardiol Pol 2014; 72: 847-853.

31. de Zeeuw D. Different renal protective effects of atorvastatin and rosuvastatin in diabetic and non-diabetic renal patients with proteinuria. Results of the PLANET trials. 2010 European Renal Association - European Dialysis and Transplant Association Congress; June 27, 2010; Munich, Germany.

32. Wożakowska-Kapłon B. Terapia hipercholesterolemii w schorzeniach układu sercowo-naczyniowego – jaki cel, jaka statyna, jaka dawka? Fol Cardiol 2014; 9(1): 55-66.